• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Broadfoot Jill Marie

    6/6/25 4:00:04 PM ET
    $CUE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUE alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Broadfoot Jill Marie

    (Last) (First) (Middle)
    C/O CUE BIOPHARMA, INC.
    40 GUEST STREET

    (Street)
    BOSTON MA 02135

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    06/04/2025
    3. Issuer Name and Ticker or Trading Symbol
    Cue Biopharma, Inc. [ CUE ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24.1 - Power of Attorney
    No securities are beneficially owned.
    /s/ Jill Marie Broadfoot by Colin Sandercock, attorney-in-fact 06/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CUE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CUE

    DatePrice TargetRatingAnalyst
    3/13/2024$6.00Buy
    Jefferies
    6/26/2023$10.00Outperform
    Oppenheimer
    11/21/2022$7.00Overweight
    Piper Sandler
    1/13/2022$20.00Buy
    H.C. Wainwright
    1/3/2022$28.00Buy
    Craig Hallum
    More analyst ratings

    $CUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Broadfoot Jill Marie

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      6/6/25 4:00:05 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Broadfoot Jill Marie

      3 - Cue Biopharma, Inc. (0001645460) (Issuer)

      6/6/25 4:00:04 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF FINANCIAL OFFICER Millar Kerri-Ann

      4 - Cue Biopharma, Inc. (0001645460) (Issuer)

      3/25/25 4:00:10 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

      Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 million in follow-on capital raise Successfully regained worldwide rights for lead autoimmune program, CUE-401, with potential to become a new standard of care for autoimmune and inflammatory diseases Virtual Event planned for May 15, 2025 at 11 AM ET, featuring two prominent Key Opinion Leaders in the field of Immunology BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeuti

      5/12/25 4:05:00 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Host Virtual Investor Event on May 15, 2025

      Mobilizing the Immune System: Cue Biopharma's Novel Biologics Portfolio Event Virtual Event will Feature Key Opinion Leaders Richard DiPaolo, PhD, and Andrew Cope, MD, PhD BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will host a virtual investor event on Thursday, May 15, 2025 at 11:00 AM ET. To register, click here. The virtual event will feature key opinion leaders (KOLs) Richard DiPaolo, PhD (Saint Louis University) and And

      5/8/25 8:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease and cancer, today announced that it will participate in a fireside chat at the Citizens Life Sciences Conference being held in New York, May 7-8, 2025. During the fireside chat, Cue Biopharma will discuss progress on its programs from the Immuno-STAT™ platform including the CUE-100 series, CUE-401, and CUE-501, which was recently partnered with Boehringer Ingelheim for T cell mediated targeted depletion of specific B cells to

      5/5/25 10:00:00 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Cue Biopharma with a new price target

      Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00

      3/13/24 7:30:48 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Cue Biopharma with a new price target

      Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00

      6/26/23 7:24:09 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Cue Biopharma with a new price target

      Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00

      11/21/22 7:39:31 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CUE
    SEC Filings

    See more
    • Cue Biopharma Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders

      8-K - Cue Biopharma, Inc. (0001645460) (Filer)

      6/10/25 4:00:08 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Cue Biopharma Inc.

      DEFA14A - Cue Biopharma, Inc. (0001645460) (Filer)

      5/27/25 8:00:19 AM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cue Biopharma Inc.

      SCHEDULE 13G/A - Cue Biopharma, Inc. (0001645460) (Subject)

      5/16/25 4:01:24 PM ET
      $CUE
      Biotechnology: Pharmaceutical Preparations
      Health Care